ALBI serves as a predictive factor of tolerability of patients with Stage II/III gastric cancer to adjuvant S-1 monotherapy after curative gastrectomy
- Conditions
- gastric cancer
- Registration Number
- JPRN-jRCT1090220373
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients started S-1 adjuvant monotherapy within 6 weeks after surgery.
Exclusion Criteria
Patients received adjuvant chemotherapy with other drugs, as well as those who experienced recurrence within 6 months after gastrectomy.
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To identify a predictive factor for tolerability of postoperative adjuvant S-1 monotherapy for gastric cancer (GC)
- Secondary Outcome Measures
Name Time Method